Inovio Pharmaceuticals Traded as NASDAQ: INO Industry Biotechnology Founded 1983 Headquarters Plymouth Meeting, Pennsylvania Key people J. Joseph Kim (President and CEO) Website inovio.com
Inovio Pharmaceuticals is an American biotechnology company focused on the discovery, development, and commercialization of synthetic DNA products for treating cancers and infectious diseases. In April 2020, Inovio was among some 100 companies, academic centers, or research organizations developing a vaccine candidate for treating people infected with the COVID-19 coronavirus, with 115 total vaccine candidates in development.[1][2] Contents
1 Technology 2 Vaccine development 2.1 Clinical research for a coronavirus vaccine 3 See also 4 References 5 Further reading 6 External links
Technology See also: COVID-19 vaccine § Vaccine candidates
The Inovio technology is based on inserting engineered DNA into cells where it becomes incorporated into proteins involved in the immune response to cancers and viruses by producing T cells and antibodies that aid recovery from infection.[3] The technology can be "targeted" to specific types of cancer and immune diseases, such as those produced by a virus.[3]
During a meeting of the White House Coronavirus Task Force in March 2020, CEO, Joseph Kim, said that Inovio scientists had designed a vaccine candidate (INO-4800) for the COVID-19 coronavirus in January in just three hours after the virus genetic sequence was first published.[4] Vaccine development See also: COVID-19 vaccine § 2020 projects
In a 2016 dose-escalation Phase I clinical trial to assess safety after intramuscular injection in healthy adults, the Inovio vaccine candidate, INO-4700 (also called GLS-5300 for development against Middle East respiratory syndrome (MERS) coronavirus), proved to be safe with only mild symptoms and no adverse effects.[5] The trial also demonstrated immunogenicity by dose-independent immune responses detected in more than 85% of subjects after two vaccinations that were durable a year later.[5]
In January 2020, the Coalition for Epidemic Preparedness Innovations (CEPI) announced it would grant of up to $9 million to develop a vaccine against SARS-CoV-2.[6] In February 2020 after receiving details of the genetic sequence of the coronavirus, Inovio announced that it had produced a preclinical DNA-based vaccine as a potential therapy for COVID-19.[4][7] Inovio is in competition to develop a coronavirus vaccine with other biotechnology companies, such as Vaxart, Novavax, and Moderna.[1][2][8][9] Clinical research for a coronavirus vaccine See also: COVID-19 vaccine § Clinical trials
Inovio is collaborating with a Chinese firm in order to speed its acceptance by regulatory authorities in China, with plans to perform human clinical trials of a coronavirus vaccine in the first half of 2020.[1][10] Inovio has partnerships with manufacturers to scale up production of a vaccine if preliminary efficacy trials are successful.[7]
In April 2020, the company began human Phase I safety studies of its lead vaccine (INO-4800) for immunization against the COVID-19 coronavirus.[1]
News 
Market Data 
Discover 
